

Program



WELCOME 9:00am

Mrs Lusia Guthrie, Interim CEO, BioMelbourne Network

SESSION 1 9:00am

Market Pull & Opportunities

Chair: Dr Elane Zelcer PhD, FAICD, Accelerating Commercialisation

Dr Andreas C. Pfahnl, ScD, Nortech Medical Devices

'How technologies enabling device miniaturization can address clinical needs'

Ms Kathy Connell, Johnson & Johnson California Innovation Centre

'Partnering with technology companies to advance medical device innovation'

Mr Paul Brennan, PolyNovo Limited

'Lessons learnt in the development and commercial pathways'

[Followed by morning tea](#)

OFFICIAL OPENING 11:20am

The Hon Philip Dalidakis MP, Minister for Small Business, Innovation and Trade

SESSION 2 11:30am

Capturing Opportunities - The Research Pipeline

Chair: Prof. Sally McArthur, Swinburne University of Technology

Dr Heather St John, MIME - Monash Institute of Medical Engineering

'Fostering clinician-led device innovation - the MIME model'

Dr Dean Robert Freestone, University of Melbourne

'New opportunities in biotech for managing epilepsy'

Prof. Paulo De Souza, DATA61 | CSIRO

'Small implantable devices: trends, risks and hurdles'

Mr Randall S. Nelson, Evergreen Medical Technologies, Inc. MN

'Implantable devices: transition from research to development'

SESSION 2 continued...

Q&A Session

Panel:

Dr Heather St John, MIME - Monash Institute of Medical Engineering

Dr Dean Robert Freestone, University of Melbourne

Prof. Paulo De Souza, DATA61 | CSIRO

Mr Randall S. Nelson, Evergreen Medical Technologies, Inc. MN

[Followed by lunch](#)

SESSION 3 1:45pm

Product Development & Commercialisation - Locking in the Opportunity

Chair: Dr Ruth Park-Jones, University of Melbourne

Ms Elpis Barons, Trajan Scientific and Medical

'Clinical trial strategy: the commercial context'

Mr Toby McSweeney, Hydrix

'Developing an active implantable - a risk driven design approach'

Mr Amos Meltzer, SmartStent Pty Limited

'Endovascular brain machine interface'

Dr John Parker, Saluda Medical

'Closed loop neurostimulation: from idea to human trials'

[Followed by afternoon tea](#)

SESSION 4 4:15pm

Whole of Venture Budget & Funding Strategies

Chair: Mr David Blake, BioShares

Panel:

Mr Andrew Maxwell, Chatsworth Associates Pty Ltd

Dr Rob Crombie, Accelerating Commercialisation

Dr Graeme Wald, OneVentures Pty Ltd

Ms Penelope Lane, Department of Economic Development (DEDJTR)

Dr Ingmar Wahlqvist, Brandon Capital Partners

SESSION 5 5:30pm

Networking Session